See more : Posiflex Technology, Inc. (8114.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Relay Therapeutics, Inc. (RLAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relay Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Zenitaka Corporation (1811.T) Income Statement Analysis – Financial Results
- Rosier SA (ENGB.BR) Income Statement Analysis – Financial Results
- Nippon Accommodations Fund Inc. (NIPPF) Income Statement Analysis – Financial Results
- Aerodrome Group Ltd (ARDM.TA) Income Statement Analysis – Financial Results
- Praj Industries Limited (PRAJIND.BO) Income Statement Analysis – Financial Results
Relay Therapeutics, Inc. (RLAY)
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 25.55M | 1.38M | 3.03M | 82.65M | 0.00 | 0.00 |
| Cost of Revenue | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| Gross Profit | 20.28M | -2.75M | -896.00K | 79.11M | -2.85M | -2.15M |
| Gross Profit Ratio | 79.37% | -199.06% | -29.58% | 95.71% | 0.00% | 0.00% |
| Research & Development | 330.02M | 246.36M | 172.65M | 99.86M | 70.31M | 41.03M |
| General & Administrative | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Other Expenses | 0.00 | -20.00K | -4.00K | -16.00K | -58.00K | -9.00K |
| Operating Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Cost & Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Interest Income | 31.05M | 8.79M | 830.00K | 3.40M | 8.80M | 1.11M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| EBITDA | -374.15M | -306.82M | -222.18M | -52.25M | -81.20M | -47.74M |
| EBITDA Ratio | -1,464.62% | -23,361.98% | -2,948.70% | -63.21% | 0.00% | 0.00% |
| Operating Income | -373.00M | -299.28M | -364.70M | -55.80M | -84.05M | -49.89M |
| Operating Income Ratio | -1,460.11% | -21,670.89% | -12,040.21% | -67.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.03M | 8.77M | 826.00K | 3.38M | 8.74M | 1.10M |
| Income Before Tax | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.79M |
| Income Before Tax Ratio | -1,338.66% | -21,036.13% | -12,012.94% | -63.41% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.25M | 132.94M | -3.40M | -8.80M | 1.10M |
| Net Income | -341.97M | -254.26M | -496.81M | -49.01M | -66.50M | -48.79M |
| Net Income Ratio | -1,338.66% | -18,411.22% | -16,401.72% | -59.30% | 0.00% | 0.00% |
| EPS | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| Weighted Avg Shares Out | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
| Weighted Avg Shares Out (Dil) | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
Why Relay Therapeutics Is Up 30% This Week
Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
Source: https://incomestatements.info
Category: Stock Reports